Curcumin supplementation in cancer patients under cisplatin treatment

Phase 3

Recruiting

• Conditions: Cancer types.; Malignant neoplasm of ovary, Malignant neoplasm of breast; C56, C50

• Registration Number: IRCT20190305042939N2
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 August 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Patients with malignancy who receive cisplatin for the first time in their treatment regimens
GFR higher than 60 mL/min based on CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
The patient be able to receive curcumin orally

Exclusion Criteria

Patients with active infection or symptoms of sepsis
Patients who have received nephrotoxic drugs such as aminoglycoside, amphotericin, vancomycin, colistin, media contrast, calcineurin inhibitors or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for the past 72 hours
Patients who have a history of taking cisplatin
Patients who may experience complications or allergic reactions to curcumin during treatment
Patients who had a history of acute kidney injury ( AKI ) before entering the study
The patient's unwillingness to cooperate during the research
Patients with bilirubin above 2 mg / dl or liver enzymes above 2.5 times the normal level

Study & Design

• Study Type: interventional
• Study Design: Not specified